Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROGLYCERIN IN DEXTROSE 5% vs IMDUR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels and causing venous and arterial dilation.
Isosorbide mononitrate is a nitrate vasodilator that relaxes vascular smooth muscle via conversion to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates veins (venodilation) with lesser effects on arteries, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Acute angina pectoris,Prophylaxis of angina,Acute myocardial infarction (to reduce preload and afterload),Heart failure (off-label use for acute decompensated heart failure),Hypertensive crisis (off-label use for severe hypertension)
Prevention of angina pectoris due to coronary artery disease,Off-label: chronic heart failure (as adjunctive therapy), esophageal spasm
Intravenous infusion: Initial 5 mcg/min, titrate by 5 mcg/min every 3-5 minutes to hemodynamic effect; usual maintenance 10-200 mcg/min. Sublingual: 0.3-0.6 mg every 5 minutes up to 3 doses. Topical: 1-2 inches every 8 hours.
Initial: 30-60 mg orally once daily; titrate to 120 mg once daily as tolerated. Maximum: 240 mg once daily.
Terminal elimination half-life: 1–4 minutes; clinical context: rapid clearance due to extensive metabolism by glutathione-S-transferase and glutathionylation.
Terminal elimination half-life of isosorbide mononitrate is approximately 5 hours. This supports once-daily dosing for IMDUR (extended-release formulation) due to prolonged absorption phase.
Extensively metabolized in the liver by glutathione-dependent organic nitrate reductase, and to a lesser extent via cytochrome P450 (CYP3A4). Primary metabolite is 1,2-glyceryl dinitrate (active).
Primarily hepatic metabolism via denitration and glucuronidation; isosorbide mononitrate is the active metabolite of isosorbide dinitrate and does not undergo significant first-pass metabolism.
Renal: ~33% as intact drug; hepatic metabolism accounts for >90% of clearance; biliary/fecal: negligible.
Isosorbide dinitrate (IMDUR active metabolite? Actually IMDUR is isosorbide mononitrate, the active metabolite of isosorbide dinitrate. For isosorbide mononitrate: renal excretion is approximately 96% as metabolites, with about 2% unchanged; biliary/fecal excretion is minimal, <2%.
~60% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Less than 5%, primarily to albumin. Very low protein binding, which contributes to high free fraction.
Vd: 0.3 L/kg; reflects distribution into vascular smooth muscle and minimal tissue penetration.
Volume of distribution is approximately 0.6-0.7 L/kg for isosorbide mononitrate. This moderate Vd indicates distribution into total body water and some tissue binding.
Intravenous: 100%; sublingual: ~40% (first-pass hepatic metabolism); oral: <10% due to extensive first-pass effect.
Oral bioavailability is nearly 100% for isosorbide mononitrate due to lack of first-pass metabolism (unlike isosorbide dinitrate). For IMDUR extended-release, relative bioavailability is comparable to immediate-release, with controlled release properties.
No specific dose adjustment required for renal impairment; monitor for volume status and hypotension.
No dosage adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, use with caution; consider starting at 30 mg once daily and titrate slowly.
Child-Pugh Class A: No adjustment. Class B: Reduce initial dose by 50%. Class C: Avoid use or reduce initial dose by 75%.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%; start at 30 mg once daily. Child-Pugh Class C: Contraindicated or use with extreme caution; start at 30 mg once daily with careful monitoring.
Not FDA-approved for pediatric use. Limited data: IV infusion 0.25-0.5 mcg/kg/min, titrate to effect; max 5 mcg/kg/min.
Not approved for pediatric use. Limited data: 0.5-2 mg/kg orally once daily, not to exceed 120 mg once daily.
Lower initial doses recommended due to increased sensitivity; start at 5 mcg/min IV or 0.3 mg sublingual; monitor for hypotension.
Start at 30 mg once daily; titrate slowly due to increased sensitivity and risk of hypotension.
NOT available in this formulation. Nitroglycerin products do not carry a black box warning.
Not recommended for use in patients with acute myocardial infarction (MI) or congestive heart failure (CHF) requiring rapid hemodynamic monitoring; use only under close clinical observation.
Hypotension (severe hypotension may occur, especially with hypovolemia),Bradycardia and paradoxical tachycardia,Increased intracranial pressure (use cautiously in head trauma or intracranial hemorrhage),Tolerance to nitrates with prolonged use (intermittent dosing recommended),Methemoglobinemia (rare, risk with high doses or prolonged infusion),Drug interactions with phosphodiesterase inhibitors (e.g., sildenafil) causing severe hypotension
Hypotension: may cause severe hypotension, especially with upright posture,Tolerance: continuous use may lead to tolerance and cross-tolerance to other nitrates; use with a daily nitrate-free interval,Headache: often occurs but may diminish with continued use,Glaucoma: controversial; generally considered safe,Volume depletion: increased risk of hypotension
Hypersensitivity to nitroglycerin,Concurrent use of phosphodiesterase inhibitors (e.g., sildenafil, tadalafil, vardenafil),Severe anemia,Increased intracranial pressure,Constrictive pericarditis or cardiac tamponade,Severe hypotension (systolic BP < 90 mm Hg),Acute myocardial infarction with right ventricular involvement,Obstructive cardiomyopathy (relative contraindication)
Hypersensitivity to isosorbide mononitrate or other nitrates,Concurrent use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) due to risk of severe hypotension,Severe anemia,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Acute circulatory failure or shock
Avoid alcohol; may cause severe hypotension and reflex tachycardia. No other significant food interactions.
Avoid high-fat meals as they may delay absorption. No specific food interactions; alcohol may increase hypotensive effects.
Nitroglycerin is generally considered to have low teratogenic potential. In the first trimester, there is no evidence of increased risk of major congenital malformations from human data. However, animal studies are insufficient to rule out risk. During the second and third trimesters, nitroglycerin is used for tocolysis and management of hypertensive emergencies without documented fetal harm, but potential for maternal hypotension leading to reduced uteroplacental perfusion exists. Overall, FDA assigns category C (risk cannot be ruled out).
FDA Pregnancy Category C. In animal studies, isosorbide mononitrate (IMDUR) caused embryotoxicity and fetotoxicity at high doses. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus. First trimester: No specific malformation pattern identified. Second and third trimesters: Potential risk of fetal hypotension and reduced placental perfusion due to maternal vasodilation.
Nitroglycerin is excreted into breast milk in minimal amounts; the M/P ratio is not established. Concentrations are likely too low to cause adverse effects in the nursing infant. Based on limited data, nitroglycerin is considered compatible with breastfeeding, but caution is recommended, especially in infants with cardiovascular instability.
Unknown if isosorbide mononitrate is excreted in human breast milk. M/P ratio not established. Caution advised; consider discontinuing nursing or drug, balancing importance of drug to mother.
Pharmacokinetic changes during pregnancy (increased plasma volume, altered drug metabolism) may necessitate dose titration to effect. No standard dose adjustment is defined; clinicians should initiate at low doses and titrate based on maternal blood pressure and uterine perfusion. The typical starting dose of 5 mcg/min intravenous is appropriate, with incremental increases guided by clinical response. Avoid bolus doses to prevent hypotension.
No specific dose adjustments recommended for pregnancy; however, hemodynamic changes (increased plasma volume, cardiac output) may alter pharmacokinetics. Start at lowest effective dose and titrate based on maternal response and tolerability.
For IV nitroglycerin in D5W, use non-PVC tubing (light-sensitive) and inline filter; avoid abrupt discontinuation to prevent rebound hypertension; titrate to chest pain relief or hemodynamic parameters; monitor for hypotension and bradycardia; tolerance may develop after 24 hours of continuous infusion.
Imdur (isosorbide mononitrate) is an extended-release nitrate used for angina prophylaxis. Avoid concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension. Tachyphylaxis can occur with continuous use; maintain a daily nitrate-free interval (typically 10-12 hours) to preserve efficacy. Do not crush or chew extended-release tablets. Monitor blood pressure and heart rate during initiation. Use with caution in patients with hypertrophic obstructive cardiomyopathy, aortic stenosis, or volume depletion.
Report any chest pain, severe headache, or dizziness immediately.,Avoid alcohol consumption while on this medication.,Do not stop infusion suddenly without medical supervision.,Remain lying down if dizzy or lightheaded.,Inform all healthcare providers of nitroglycerin use.
Take Imdur exactly as prescribed, usually once daily in the morning to maintain a nitrate-free interval.,Do not crush, chew, or cut the tablet; swallow it whole with a glass of water.,Avoid taking erectile dysfunction medications (e.g., Viagra, Cialis, Levitra) while on Imdur, as this can cause a dangerous drop in blood pressure.,If you experience headache, it may indicate the drug is working; acetaminophen can help. Inform your doctor if headaches persist.,Store at room temperature, away from moisture and heat.
"Concomitant use of nitroglycerin, a vasodilator that increases cyclic guanosine monophosphate (cGMP) in vascular smooth muscle, and acebutolol, a cardioselective beta-1 adrenergic blocker, can lead to excessive hypotension and reflex tachycardia. Acebutolol may blunt the compensatory sympathetic response to nitroglycerin-induced vasodilation, while nitroglycerin can counteract the negative chronotropic effects of acebutolol, resulting in unopposed vagal tone and potential bradycardia. This interaction increases the risk of syncope, dizziness, and cardiovascular collapse, particularly in patients with volume depletion or pre-existing heart failure."
"Amobarbital, a barbiturate with hepatic enzyme-inducing properties, may enhance the metabolism of nitroglycerin, potentially reducing its efficacy. However, the primary concern is that amobarbital can cause significant hypotension via central nervous system depression and vasodilation, which, when combined with the vasodilatory effects of nitroglycerin, may lead to additive hypotensive effects, increasing the risk of severe hypotension, syncope, and cardiovascular collapse. This interaction is particularly relevant in patients with coronary artery disease or heart failure, where maintaining adequate blood pressure is critical."
"Concurrent administration of clofarabine, a purine nucleoside antimetabolite, and nitroglycerin, a vasodilator for angina, may lead to additive hypotension. Clofarabine itself can induce hypotension as an adverse effect, and nitroglycerin directly relaxes vascular smooth muscle, resulting in decreased blood pressure. This combination increases the risk of severe hypotension, potentially leading to dizziness, syncope, or falls, especially in patients with pre-existing hypotension or volume depletion."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROGLYCERIN IN DEXTROSE 5% vs IMDUR, answered by our medical review team.
NITROGLYCERIN IN DEXTROSE 5% is a Nitrate Vasodilator that works by Nitroglycerin is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels and causing venous and arterial dilation.. IMDUR is a Nitrate Vasodilator that works by Isosorbide mononitrate is a nitrate vasodilator that relaxes vascular smooth muscle via conversion to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates veins (venodilation) with lesser effects on arteries, reducing preload and afterload, thereby decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROGLYCERIN IN DEXTROSE 5% and IMDUR depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROGLYCERIN IN DEXTROSE 5% is: Intravenous infusion: Initial 5 mcg/min, titrate by 5 mcg/min every 3-5 minutes to hemodynamic effect; usual maintenance 10-200 mcg/min. Sublingual: 0.3-0.6 mg every 5 minutes up to 3 doses. Topical: 1-2 inches every 8 hours.. The standard adult dose of IMDUR is: Initial: 30-60 mg orally once daily; titrate to 120 mg once daily as tolerated. Maximum: 240 mg once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROGLYCERIN IN DEXTROSE 5% and IMDUR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROGLYCERIN IN DEXTROSE 5% is classified as Category C. Nitroglycerin is generally considered to have low teratogenic potential. In the first trimester, there is no evidence of increased risk of major congenital malformations from human. IMDUR is classified as Category C. FDA Pregnancy Category C. In animal studies, isosorbide mononitrate (IMDUR) caused embryotoxicity and fetotoxicity at high doses. There are no adequate and well-controlled studies . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.